Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...

Early in his career he devised a contraption capable of distinguishing certain mineral signatures underground, and he later took part in one of the high adventures of Canada’s storied mining history ...

Community members are launching into action to help fund medical bills for Carpinterian Lisa Burch, 61, who has Amyotrophic ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

People living with motor neuron disease (MND) will have more opportunities to participate in groundbreaking research, thanks ...

Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in ...